Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

NeuroOp Guru

The Residency Report

iOpeners

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Videos

Q&A: Vicky Demas on the importance of simplifying retinal screenings and incorporating AI

Articles

New World Medical launches non-valved glaucoma drainage device, Ahmed ClearPath ST

Neurotech Pharmaceuticals enhances its leadership by appointing Peter J. McDonnell, MD, a leading ophthalmology expert, to its Board of Directors.

Neurotech Pharmaceuticals appoints Peter J. McDonnell, MD, to Board of Directors

MCO-010 receives Orphan and RMAT designations, highlighting its potential as a groundbreaking therapy for various retinal dystrophies.

EMA grants Orphan designations to MCO-010, FDA grants RMAT in Stargardt disease

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times – Clinical Insights for Eye Specialists

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

View

Orbis International

Derek Hodkey Orbis CEO 

David Hutton of Ophthalmology Times talks with Derek Hodkey, CEO and president of Orbis International, about 2023 in review as well as plans for the company moving into 2024. 

- This transcript has been edited for clarity.

Orbis is an international nonprofit delivering sight-saving programs in over 200 countries and regions worldwide so that individuals, families, and communities can thrive. Currently, around 1 billion people across the globe live with completely avoidable blindness and vision loss. For over four decades, Orbis has been tackling this challenge by building strong and sustainable eye care systems that leave a lasting legacy of vision. Orbis runs dedicated in-country programs in Africa, Asia, the Caribbean, and Latin America; develops and implements innovative training and technology, including an award-winning telemedicine and e-learning platform, 

; and operates the world's first and only 

, a fully accredited ophthalmic teaching hospital on board an MD-10 aircraft. For the past ten consecutive years, Orbis has achieved 

's coveted four-star rating for demonstrating strong financial health and commitment to accountability and transparency, placing Orbis in the top 3% of U.S. charities. For the past two years, Orbis has earned 

's platinum Seal of Transparency. In 2022, Orbis earned "accredited charity" status from the 

 by meeting all 20 of their standards for charity accountability. To learn more, please visit 

SAP Partner

Orbis CEO and president gives insight into 2024 plans

Orbis CEO and president gives insight into 2024 plans

Video Transcript

Newsletter